Invention Novelty: This technology provides purified human IgG antibodies isolated from plasma cells from a Neuromyelitis Optica (NMO) positive patient.
Value Proposition: NMO or Devic’s disease is a rare inflammatory disease in the optic nerves, and spinal cord where specific disease-related antibodies trigger an autoimmune response in the body. To better understand these mechanisms, purified antibodies samples are needed but difficult to obtain due to the rarity of the disease and processing technique. This technology offers purified IgG antibodies which can be used as an investigative tool to learn more about the immunological dynamics in NMO. Other advantages include:
Technical Details: Johns Hopkins researchers have purified human immunoglobulins (IgG) from the plasma cells in a patient that tested positive for NMO via a NMO- IgG serum immunoassay. These samples were obtained from plasmapheresis which removes plasma cells containing circulating antibodies associated with disease. This technology also include the methods for isolation and purification of the IgG component with enriched NMO-IgG to serve as tool to further study of human immune system responses to NMO.
Looking for Partners: To develop & commercialize the technology as a research tool for investigating human immunological mechanisms in patients with NMO.
Stage of Development: Ready for use
Data Availability: “Under CDA / NDA”
Patent Status: Tangible Material
Publication(s)/Associated Cases: BMC Neurology 2013, 13:104 Any data available?
